Mustang Bio, Inc. (MBIO) financial statements (2021 and earlier)

Company profile

Business Address 2 GANSEVOORT STREET
NEW YORK, NY 10014
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments61346127
Cash and cash equivalents61163527
Short-term investments 1826 
Restricted cash and investments1   
Receivables 00 
Prepaid expense 10 
Other undisclosed current assets1   
Total current assets:63356127
Noncurrent Assets
Operating lease, right-of-use asset1
Property, plant and equipment87  
Restricted cash and investments111 
Other noncurrent assets000 
Other undisclosed noncurrent assets  1 
Total noncurrent assets:1082 
TOTAL ASSETS:73436327
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:6531
Accounts payable2   
Other undisclosed accounts payable and accrued liabilities4531
Debt2   
Due to related parties1  0
Other undisclosed current liabilities 002
Total current liabilities:8643
Noncurrent Liabilities
Long-term debt and lease obligation14   
Long-term debt, excluding current maturities12   
Operating lease, liability2
Liabilities, other than long-term debt 10 
Accounts payable and accrued liabilities 10 
Total noncurrent liabilities:1410 
Total liabilities:22643
Stockholders' equity
Stockholders' equity attributable to parent52366024
Common stock0000
Common stock, value, subscriptions52104
Additional paid in capital1721139937
Accumulated deficit(125)(79)(48)(17)
Total stockholders' equity:52366024
TOTAL LIABILITIES AND EQUITY:73436327

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
Operating expenses(46)(31)(32)(11)
Operating loss:(46)(31)(32)(11)
Nonoperating income (expense)(1)10(1)
Interest and debt expense(2)(0)(0)(0)
Net loss:(48)(31)(31)(13)
Other undisclosed net income attributable to parent2000
Net loss available to common stockholders, diluted:(46)(31)(31)(13)

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
Net loss:(48)(31)(31)(13)
Comprehensive loss, net of tax, attributable to parent:(48)(31)(31)(13)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: